Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
